Trials / Completed
CompletedNCT00817986
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- XenoPort, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arbaclofen placarbil, 20 mg | tablets |
| DRUG | Placebo | tablets |
| DRUG | Arbaclofen placarbil, 30 mg | tablets |
| DRUG | Arbaclofen placarbil, 40 mg | tablets |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2009-01-07
- Last updated
- 2021-02-21
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00817986. Inclusion in this directory is not an endorsement.